Zacks Investment Research
06 Oct 2026, 15:46 UTC · 1h ago
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now
Impact · against what's priced in
The article provides no catalyst for Cardinal Health as its core growth narratives and earnings trajectories are already reflected in the current valuation. The projected long-term earnings growth and recent pharma segment momentum are already baked into the price.
- CAH+0.00
Already priced in
- The price assumes
The 21% profit increase in the Pharmaceutical and Specialty Solutions segment to $645 million in the fourth quarter.
The article highlights the 21% profit increase in the pharma segment in Q4 FY2026, but the market has already fully absorbed this performance.
What CAH's price assumes · Sep 4
